HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pregabalin Improves Pain Scores in Patients with Fibromyalgia Irrespective of Comorbid Osteoarthritis.

AbstractOBJECTIVE:
Fibromyalgia (FM) is a chronic pain disorder with patients frequently suffering from comorbid conditions, including osteoarthritis (OA). Data on how FM patients with comorbid OA respond to recommended therapies (such as pregabalin) could help their treatment.
DESIGN:
This was a pooled exploratory analysis of three randomized placebo-controlled clinical trials of pregabalin in FM patients to assess the impact of comorbid OA on the response to pregabalin.
METHODS:
Patients were divided into those with and without comorbid OA. Difference in change in least squares (LS) mean pain score at endpoint (assessed by 0-10 numeric rating scale, controlled for baseline pain score) with pregabalin (300 mg/day and 450 mg/day) vs placebo was assessed. Changes in Patient Global Impression of Change (PGIC) responders and Fibromyalgia Impact Questionnaire (FIQ) total score were also assessed.
RESULTS:
There were 1665 patients in the analysis set (558, placebo; 552, pregabalin 300 mg/day; 555, pregabalin 450 mg/day), including 296 with comorbid OA. Pregabalin 450 mg/day significantly improved the LS mean (95% confidence interval) difference in pain score vs placebo in patients with (0.99 [0.44, 1.55], P < 0.001), and without (0.64 [0.39, 0.89], P < 0.001) OA. Improvements with pregabalin 300 mg/day with (0.31 [-0.25, 0.86], P = 0.276) and without (0.51 [0.25, 0.76], P < 0.001) OA were not consistently significant. Improvements in PGIC and FIQ total score were observed in patients with and without comorbid OA.
CONCLUSIONS:
FM patients with or without comorbid OA respond to treatment with pregabalin 450mg/day with significant improvements in pain intensity scores. These data could provide guidance to healthcare professionals treating these patients.
AuthorsCharles E Argoff, Birol Emir, Ed Whalen, Marie Ortiz, Lynne Pauer, Andrew Clair
JournalPain medicine (Malden, Mass.) (Pain Med) Vol. 17 Issue 11 Pg. 2100-2108 (11 2016) ISSN: 1526-4637 [Electronic] England
PMID27257288 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Copyright© 2016 American Academy of Pain Medicine. All rights reserved. For permissions, please e-mail: [email protected].
Chemical References
  • Analgesics
  • Pregabalin
Topics
  • Adolescent
  • Adult
  • Aged
  • Analgesics (pharmacology, therapeutic use)
  • Comorbidity
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Female
  • Fibromyalgia (diagnosis, drug therapy, epidemiology)
  • Humans
  • Male
  • Middle Aged
  • Osteoarthritis (diagnosis, drug therapy, epidemiology)
  • Pain (diagnosis, drug therapy, epidemiology)
  • Pain Measurement (drug effects, methods)
  • Pregabalin (pharmacology, therapeutic use)
  • Treatment Outcome
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: